Toronto, Ontario--(Newsfile Corp. - Le 11 novembre/November 2022) - Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") announced today that its Plan of Arrangement with Skye Bioscience, Inc. ("Skye") has closed and that it has entered into agreements to divest its remaining cannabis assets and licenses, including its Quebec cannabis production facility.

Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announced today that its Plan of Arrangement with Skye Bioscience, Inc. ("Skye") has closed and that it has entered into agreements to divest its remaining cannabis assets and licenses, including its Quebec cannabis production facility.

VANCOUVER, BC, Nov. 9, 2022 /CNW/ - The following issues have been halted by IIROC:

Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction

Vancouver, British Columbia--(Newsfile Corp. - October 18, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that it has provided a short-term bridge loan of US$700,000 to Skye Bioscience, Inc. ("Skye") in order to provide Skye with additional working capital until the closing of their Arrangement.

Additional capital from Arrangement Agreement expected to fund Skye's Phase 1 and 2 clinical studies of proprietary synthetic cannabinoid-derivative therapeutic targeting glaucoma

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the quarter ended June 30, 2021.

Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that on August 25, 2022, the Supreme Court of British Columbia issued a final order approving the Company's previously announced plan of arrangement (the "Arrangement") with Skye Bioscience Inc. ("Skye") (OTCQB: SKYE) and declaring that the Arrangement was procedurally and substantively fair and reasonable. The Arrangement was previously approved by Emerald's shareholders at the Company's annual general and special meeting held August 19, 2022. 

HYTN Innovations Inc. (“HYTN” or the “Company”) (CSE: HYTN) is pleased to announce that its wholly owned subsidiary, HYTN Cannabis Inc., has been awarded a license (the “License”) by Health Canada allowing for the sale of cannabis for medical...

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") reports that its shareholders voted in favour of all resolutions presented at its annual and special meeting held today at 10:00 am PT.

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional background on its transaction (the "Transaction") with Skye Bioscience Inc. (OTCQB: SKYE) ("Skye") pursuant to the terms of an arrangement agreement dated May 11, 2022, as amended (the "Arrangement Agreement").

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announces that it has identified matters which require the Company to make restatements (the "Restatements") in respect of its interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to (a) cash and cash equivalents (b) revenue from sale of goods and (c) impairment of assets.

MONTREAL, Aug. 4, 2022 /CNW Telbec/ - Certain shareholders (the "Opposing Shareholders") of Emerald Health Therapeutics Inc. ("Emerald") (CSE: EMH); (OTCQX: EMHTF), announce that they oppose the announced plan of arrangement (the "Plan") between Emerald and Skye Biosciences Inc. ("Skye") (OTCQB: SKYE).

Vancouver, British Columbia--(Newsfile Corp. - July 12, 2022) - Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (CSE: EMH) (OTCQB: EMHTF) reports that it has received an Order of the British Columbia Securities Commission ("BCSC") revoking the management cease trade order ("MCTO") issued by the BCSC on May 3, 2022.

Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") has reported financial results for the quarter ended March 31, 2021.

Company also provides bi-weekly MCTO status update

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").

Vancouver, British Columbia--(Newsfile Corp. - June 3, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") is providing a status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").

Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald") and Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye") announced today that the companies have entered into a definitive agreement with respect to a transaction to be completed by way of a Plan of Arrangement (the "Arrangement") whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction. Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the Arrangement. The proposed Arrangement is subject to approval by each company's common stockholders and by the Supreme Court of British Columbia, Canada.

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announced today that it has transferred its US listing to the OTCQB after receiving notice from the OTC Markets Group that the Company no longer meets the listing requirements for continued listing on the OTCQX International tier.

Vancouver, British Columbia--(Newsfile Corp. - April 28, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") reports that it anticipates it will be unable to file its Annual Filings before the May 2, 2022 deadline and has applied to the British Columbia Securities Commission for a temporary management cease trade order.

HYTN Innovations Inc. ("HYTN" or the "Company) (CSE: HYTN) is pleased to announce that it has begun accepting orders directly from Provincial buyers. This news builds on HYTN’s February 22 announcement that it had been awarded approval to sell...

HYTN Innovations Inc. ("HYTN" or the “Company”) (CSE: HYTN) announces that its wholly owned subsidiary, HYTN Cannabis Inc., has been awarded a license amendment (the “License Amendment”) by Health Canada allowing for the sale of cannabis extract,...

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has entered into a binding term sheet to sell to FlowerPod LLC all patents and related intellectual property pertaining to Emerald's vaporizer cannabis puck concept in exchange for US$1 million in cash and a US$500,000 one-year interest-bearing secured promissory note. As part of the transaction, Emerald will transfer its ownership interest back to FlowerPod LLC but will retain its US$350,000 two-year interest-bearing promissory note it received from FlowerPod LLC on May 5, 2021. The transaction is scheduled to close in late Q1 2022.

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has announced the results of voting at its annual general meeting held December 30, 2021. Shareholders voted in favour of all resolutions, setting the number of directors at three, electing Jim Heppell, Punit Dhillon and Bobby Rai as directors, and appointing MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to fix remuneration for the auditors.

Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") today announced that it is exiting the recreational and medical cannabis business and pivoting to a pharmaceutical development focus. Emerald intends to seek purchasers for its recreational and medical cannabis assets to further strengthen its already strong capital position and plans significant cost cuts to decrease its monthly net burn. Emerald intends to maximize its cash position and seek business opportunities in pharmaceutical development where the Board of Emerald has significant expertise. Any such acquisitions or dispositions are subject to regulatory approval and may be subject to shareholder approval.

Emerald partners with HYTN to sell and distribute HYTN's calorie-free, fast-acting THC-infused sparkling cannabis beverages as new alternative in the rapidly growing cannabis beverage market

Emerald Patent Licensee Announces Partnership with Leading Cannabis Vaporization Technology Company, Grenco Science

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") announced today that its Chief Financial Officer, Jenn Hepburn, will be stepping down from her position at Emerald, effective October 15, 2021, to pursue other interests. She will continue in her role until that time to help with transition-related activities.

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald")  has released its financial results for the three and six months ended June 30, 2021. Full versions of Emerald's unaudited condensed interim consolidated financial statements and management discussion and analysis can be found on www.sedar.com.

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it will report its financial results for the second quarter ended June 30, 2021, after the market close on Monday, August 30, 2021. The company will host a conference call on Tuesday, August 31, 2021, at 10:30 a.m. ET.

Vancouver, British Columbia--(Newsfile Corp. - August 11, 2021) -  Further to its press release of August 6th, Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald" or the "Company") provides additional details regarding the resignation of Dr. Avtar Dhillon as director and executive chairman. On August 5th the Company became aware that Dr. Avtar Dhillon had been arrested in the United States and charged with violations of US federal securities laws with respect to trading in certain US companies unrelated to Emerald. On August 6th Dr. Dhillon resigned from all roles with the Company, as previously announced. On August 9th the Securities and Exchange Commission announced certain additional charges against Dr. Dhillon and certain other individuals not related to Emerald.

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has appointed Nick Mosgrove as VP Sales & Marketing. Mr. Mosgrove has over 15 years of sales and marketing leadership experience in the Canadian alcohol beverage and cannabis sectors.

Vancouver, British Columbia--(Newsfile Corp. - August 6, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") today announced that Avtar Dhillon, MD, has resigned from his roles as director and Executive Chairman of Emerald's board of directors for personal reasons effective immediately.

Vancouver, British Columbia--(Newsfile Corp. - July 23, 2021) -  Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald")  has retained BC Farm & Ranch Realty Corp., a real estate agent dedicated 100% to agricultural properties, to assist in the sale of its licensed greenhouse cannabis production facility in Greater Vancouver, British Columbia.

Nano Shot product debuts new Fuse(TM) brand; employs Emerald's science-based innovation to provide rapid onset and more predictable, shorter-duration effects

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has released its financial results for the three months ended March 31, 2021. Full versions of Emerald's unaudited condensed interim consolidated financial statements and management discussion and analysis can be found on www.sedar.com.

Proposed partnership would focus on developing innovative, science-backed wellness products

Emerald secures equity position in US company launching unique cannabis specialty product

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") has appointed Mr. Moe Jiwan as Chief Operating Officer effective May 10th.

Emerald hosting conference call today, May 3rd, at 10:30 am ET

Emerald to host 2020 year-end financial results conference call on Monday, May 3, 2021, at 10:30 AM ET

First-to-market rapidly-dissolving tablet offers controlled onset and offset; reflects Emerald's focus on science-based innovation and expands products available under SYNC™ Wellness brand

Vancouver, British Columbia--(Newsfile Corp. - March 17, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has formed a partnership with Medical Plants SLU, based in Almeria, Spain, in which it will provide resources and expertise to assist Medical Plants to produce medical cannabis dried flower and 2.0 products to serve emerging legal medical cannabis markets in the EU and other countries that require high-grade GMP-certified flower or derivatives.

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has applied to the Canadian Securities Exchange ("CSE") to have its common shares listed for trading on the CSE. In connection with the listing of its common shares on the CSE, Emerald will apply to the TSX Venture Exchange ("TSXV") to have its common shares delisted from trading on the TSXV.

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it will cease operations at its cannabis production facility in Greater Vancouver, British Columbia effective March 31, 2021 and will consider strategic alternatives for this facility.

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has received from Village Farms International Inc. $19.9M plus $621,534.25 in interest, representing full repayment of the promissory note issued by Village Farms to Emerald as part of its purchase of Emerald's interest in the Pure Sunfarms joint venture which closed in November 2020. This was the final payment due as part of this transaction.

Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has promoted Orville Bovenschen to the position of Senior Vice President, Operations and Rebecca Wong to Senior Vice President, Quality & Regulatory Affairs.

Vancouver, British Columbia--(Newsfile Corp. - January 13, 2021) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has settled all outstanding amounts owing to the original vendors (the "Vendors") in connection with Emerald's 2018 acquisition of Verdélite Sciences, Inc. ("Verdélite Sciences") and Verdélite Property Holdings, Inc. ("Verdélite Property" and, together with Verdélite Sciences, the "Subsidiaries").

Vancouver, British Columbia--(Newsfile Corp. - December 29, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that its partner, STENOCARE A/S, completed its first shipment and delivery of Emerald medical cannabis oil to patients in Sweden.

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") has launched and made its first shipment of its new SYNC™ 100 CBD oil to the province of Saskatchewan. Shipments to Alberta and BC are scheduled for next week, with product expected to be available for purchase online and in licensed stores before the new year.

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) -  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced that it has terminated its share purchase agreement dated July 30, 2020 (the "Agreement") with Quinto Resources Inc. ("Quinto") in respect of the proposed sale of Emerald's wholly-owned subsidiaries, Verdélite Sciences, Inc. ("Verdélite Sciences") and Verdélite Property Holdings, Inc. ("Verdélite Property" and, together with Verdélite Sciences, the "Subsidiaries"). The Subsidiaries together own and operate a premium 88,000 square foot craft cannabis production indoor facility in St. Eustache, Québec.

Emerald hosting conference call today, December 1st, at 10:30 am ET

Emerald to report Q3 financial results on November 30th and host conference call on December 1st at 10:30 am ET

Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") has completed the previously disclosed sale of its 41.3% interest in Pure Sunfarms Corp. ("PSF") to Village Farms International, Inc. ("Village Farms") (NASDAQ: VFF) (TSX: VFF) for consideration of $79,900,000.

Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) -   Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") has completed the previously disclosed sale of its 41.3% interest in Pure Sunfarms Corp. ("PSF") to Village Farms International, Inc. ("Village Farms") (NASDAQ: VFF; TSX: VFF) for consideration of $79,900,000.

Vancouver, British Columbia--(Newsfile Corp. - October 29, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") is pleased to announce that its shareholders have voted today at its annual general and special meeting (the "Meeting") to approve the sale of the Company's 41.3% interest in Pure Sunfarms Corp. ("PSF") to Village Farms International, Inc. ("Village Farms").

Combination of appealing natural flavourings and terpenes offers unique consumer experience

Processing license permits Richmond site to process consumer products and vertically integrate into potential product segments

Vancouver, British Columbia--(Newsfile Corp. - September 16, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") has closed its previously announced shares for debt financing. Further to its news release dated August 21, 2020, the Company has settled $625,000 of debt (the "Debt") payable to the holders (the "Holders") of convertible debentures of the Company issued on September 10, 2019 (the "Convertible Debentures"). The Debt represents accrued interest on the Convertible Debentures to June 30, 2020. The Debt was settled in exchange for the issuance of 3,571,428 common shares of the Company (the "Debt Shares") to the Holders at a deemed value of $0.175 per Debt Share. All Debt Shares are subject to a statutory hold period of four months plus a day from the date hereof in accordance with applicable securities legislation.

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) -  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") and STENOCARE A/S today announced that they have received special approval from the Swedish Medicines Agency to provide medical cannabis oil to Swedish patients who have applied via their doctor to use such products for treatment purposes.

VANCOUVER, BC, Sept. 8, 2020 /CNW/ - Trading resumes in:

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") is pleased to announce that it has entered into a share purchase agreement (the "Share Purchase Agreement") with Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF) ("Village Farms") in respect of the sale of the Company's interest in Pure Sunfarms Corp. ("PSF"), a joint venture that was established between the Company and Village Farms in 2017 in which the Company holds a 41.3% interest.

VANCOUVER, BC, Sept. 8, 2020 /CNW/ - The following issues have been halted by IIROC:

Quinto Resources Inc. ("Quinto") (TSXV: QIT) is pleased to announce that it has entered into a property acquisition agreement dated August 12, 2020 with Tomagold Corporation (“Tomagold”) (TSXV: LOT), and would also like to provide an update with...

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") reported financial results for the three and six months ended June 30, 2020. Full versions of the Company's unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com.

SYNC(TM) Nano Fast Action Spray uses nanoemulsion technology to enable rapid onset and shorter duration of effects; the first THC product is in-market, with CBD to follow

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2020) -  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") today announced its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping its first Cannabis 2.0 and bottled oil products. Shipments will initially be to British Columbia, with shipments to Ontario and Alberta planned to begin shortly.

Vancouver, British Columbia--(Newsfile Corp. - August 21, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") today announced that it has reached an agreement with the holders of convertible debentures of the Company issued on September 10, 2019 (the "Convertible Debentures") to settle accrued interest on the Convertible Debentures to June 30, 2020 in the amount of $625,000 by issuing an additional 3,571,428 common shares of the Company (the "Debt Shares") at a deemed value of $0.175 per share (the "Debt Settlement"). The Debt Settlement is subject to approval of the TSX Venture Exchange. All Debt Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance of the Debt Shares in accordance with applicable securities legislation.

Pure Sunfarms achieves 89% sequential quarterly growth in retail sales volume; maintains leadership in market share in Ontario and low-cost production

Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the "Company") today announced that it has established an at-the-market equity program ("ATM Program") that allows the Company to issue common shares from treasury ("Common Shares") having an aggregate gross sales price of up to $3.25 million to the public from time to time, at the Company's discretion, at the prevailing market price when issued on the TSX Venture Exchange ("TSXV") or on any other marketplace for the Common Shares in Canada. The ATM Program is effective until the earlier of April 13, 2021 and completion of the sale of the maximum amount of shares thereunder and will be activated from time to time at the Company's discretion if and when required based on the Company's working capital requirements and capital expenditures and relative cost of other funding options.

Quinto Resources Inc. ("Quinto") (TSXV: QIT) and Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) have entered into a share purchase agreement dated July 30, 2020 (the "Agreement") in respect of the sale of Emerald's...

Vancouver, British Columbia--(Newsfile Corp. - August 3, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) ("Emerald") announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald has also granted an aggregate of 175,000 restricted share units to certain employees. The restricted share units will vest one year from the grant date and convert into common shares of Emerald at a fair market value of $0.21 per common share. The stock options and restricted share units have been granted pursuant to Emerald's Omnibus Incentive Plan which has been previously approved by Emerald's shareholders and the TSX Venture.

Vancouver, British Columbia--(Newsfile Corp. - July 31, 2020) - Emerald Health Therapeutics, Inc. (TSXV: EMH)  ("Emerald") and Quinto Resources Inc. ("Quinto") (TSXV: QIT) today announced that they have entered into a share purchase agreement dated July 30, 2020 (the "Agreement") in respect of the sale of Emerald's wholly-owned subsidiaries, Verdélite Sciences, Inc. ("Verdélite Sciences") and Verdélite Property Holdings, Inc. ("Verdélite Property" and, together with Verdélite Sciences, the "Subsidiaries"). The Subsidiaries together own and operate a premium 88,000 square foot craft cannabis production indoor facility (the "Facility") in St. Eustache, Québec.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried flower products...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has terminated certain related party agreements pertaining to consulting services and a loan facility. Emerald Health Sciences Inc. ("EHS"), a control person of Emerald, and...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has further expanded its credit facility (the “Credit...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried flower products to...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its Verdélite Sciences subsidiary in St. Eustache, Québec, has launched its new Souvenir cannabis brand in the province. The Souvenir product line initially...

Verdélite Sciences (“Verdélite”) introduced its new Souvenir Cannabis brand to the Québec adult-use recreational cannabis market on June 22nd, 2020. The blue and white packaging marked with the Fleur-de-lys shows Verdélite’s commitment to the...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and ended March 31, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release on April 29th, Emerald will report its financial results for the first quarter ended March 31, 2020, after the market close on...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), is pleased to announce that it has closed its prospectus offering (the "Offering") to certain institutional accredited investors (the “Investors”), as announced on May 21,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it has terminated certain related party agreements pertaining to its cannabis cultivation operation in Metro Vancouver. Previously existing rights and continuing...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received from Health Canada its cannabis cultivation and sales...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the first quarter of 2020 for its 41.3%-owned joint venture, Pure Sunfarms. During the three months ended March 31,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and year ended December 31, 2019. Full versions of the Company’s audited consolidated financial statements and MD&A can be found on...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release on April 29th, Emerald will report audited financial results for the fourth quarter and year ended December 31, 2019 after the...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that as a result of the COVID-19 pandemic, Emerald, as well as its auditors and filing agents, have followed the recommendations of local health authorities and...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) is announcing its new nanoemulsion-based Fast Action Spray product line, an important step in Emerald’s Cannabis 2.0 strategy and a unique offering in the Canadian cannabis...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it intends to amend the terms of certain common share purchase warrants originally issued on September 9, 2019 (the “Warrants”). An aggregate of 12,500,000...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced that the first shipment of its own unique version of the cannabis strain, Chemdog, from its 100%-owned Richmond facility is now available through the BC Liquor...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its Pure Sunfarms (“PSF”) joint venture has finalized the expansion of its credit facility with its existing lender to $59 million, including accordion...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) (“Emerald”) has signed a letter of intent under which Sigma Analytical Services Inc. (“Sigma”), a full-service GMP-compliant testing laboratory for cannabis, hemp, and derived...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release dated March 3, 2020, all transactions contemplated by the settlement agreement (the "Settlement Agreement") among Emerald,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has entered into a settlement agreement (the "Settlement Agreement") with Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF," and together with...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has completed its first...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the final tranche of its $3,000,000 prospectus offering (the “Offering”), announced in its news release dated January 6, 2020. Pursuant to this final closing,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the first tranche of its $3,000,000 prospectus offering (the “Offering”) announced in its news release dated January 6, 2020. Pursuant to this initial closing,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), is pleased to announce that it has closed its previously announced shares for debt financing. Further to its news release dated January 27, 2020, Emerald has settled...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today provided an update on a previously announced shares for debt transaction. Further to its news release dated December 16, 2019, Emerald will be settling $2,816,963 (the...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that Village Farms International, Inc. ("Village Farms") has withdrawn its attempt to make an unsupported  additional equity contribution in their joint...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with certain institutional accredited investors (the “Investors”) under which the Investors have agreed, subject to certain customary...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), announced today that it has closed the initial tranche of a private placement which was announced on December 16, 2019. Private Placement Emerald has closed the initial...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has entered into a multi-year agreement (the "Agreement") with Valens GroWorks Corp. (“Valens” or “The Valens Company”) (TSXV: VLNS; OTCQX: VLNCF) to contract cannabis...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced today that it is carrying out a financing and entering into a shares for debt transaction. Private Placement Emerald intends to complete a non-brokered private...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and nine-month period ended September 30, 2019. Full versions of the Company’s unaudited condensed, interim consolidated financial...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), announced today that it closed its prospectus sale (the "Offering") to a single Canadian institutional accredited investor (the “Investor”), as announced on November 13, 2019....

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today responded to misleading public disclosure made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) yesterday in connection with their joint...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has secured a cannabis supply...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has completed planting at its indoor Québec facility, Verdélite, and expects to complete planting in the next days in the first of its two greenhouses in Metro Vancouver,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today responded to inaccurate allegations made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) in connection with their 50/50 joint venture, Pure...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the third quarter of 2019 for its BC-based, 50%-owned joint venture, Pure Sunfarms (“PSF”). The Company will report...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received organic certification for cannabis production at its Metro Vancouver operation in British Columbia, which encompasses 156,000 square feet in two greenhouses as...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has signed an agreement to become a new supplier to STENOCARE A/S (“STENOCARE”) of medical cannabis for Denmark and STENOCARE’s international markets. Since early September...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in the Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston.  Riaz Bandali, President and...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced an internal reorganization including the reduction of its workforce and other expenditures. It is at the same time reinforcing its commitment to new product...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first shipment of premium cannabis products to the Nova Scotia Liquor Corporation (NSLC) for the adult-use market. This first shipment consisted of Emerald’s...

Emerald Health Therapeutics’ (“Emerald”)(TSXV: EMH; OTCQX: EMHTF) wholly-owned production facility, Verdélite, in St. Eustache, Québec, has received from Health Canada its license amendment permitting it to sell and distribute packaged, branded...

Emerald Health Therapeutics (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that it has notified Pure Sunfarms Corp. ( the “Joint Venture”), its 50%-owned joint venture, that it does not agree that Emerald has any liability under the current Supply...

Emerald Health Therapeutics (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received from Health Canada its cultivation license amendment and has full municipal permitting for its first of two 78,000 square foot greenhouses at its organic Metro Vancouver...

Toronto, Ontario--(Newsfile Corp. - October 11, 2019) - Capital 10X President Evan Veryard sits down with Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) VP of Finance and Communications Bernie Hertel.

Emerald Health Therapeutics’ (“Emerald”)(TSXV: EMH; OTCQX: EMHTF) wholly-owned cannabis production facility, Verdélite, in St. Eustache, Quebec, has received from Health Canada a license amendment for the complete growing and processing area in its...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), today announced its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. ("Pure Sunfarms" or "PSF"), has begun shipping...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms (PSF), has formally launched its Pure Sunfarms...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), today announced that it will participate in a panel and be available for 1x1 meetings at the Eight Capital & Cassels Brock Global Cannabis Conference being held on September...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), a Canadian licenced producer of medicinal and recreational cannabis products, and HelloMD, a leading online cannabis healthcare company, have announced a partnership to...

Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") (TSXV: EMH; OTCQX: EMHTF) announces that it has closed its prospectus offering (the "Offering") to certain Canadian institutional accredited investors announced on August 28, 2019....

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received from Health Canada the amendment to its...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms (PSF), has entered into a supply agreement with the...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended June 30, 2019. Full versions of the Company’s unaudited condensed, interim consolidated financial statements and MD&A for...

Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV: EMH; OTCQX: EMHTF) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that it will present a corporate overview and be available for 1x1 meetings at the Rodman & Renshaw 21st Annual Global Investment Conference being held from...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the second quarter of 2019 for its BC-based 50%-owned joint venture, Pure Sunfarms (PSF). The Company will report its...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today provided updates on its various cultivation and processing initiatives. “With the first 1.1 million square foot (25 acre) greenhouse of our Pure Sunfarms joint venture...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has appointed Riaz Bandali as Chief Executive Officer. Mr. Bandali has over 25 years of experience in life sciences, with expertise in global operations, strategy development,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, BC. The outdoor grow area is...

Emerald Health Therapeutics, Inc.’s (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has achieved its full production run-rate of 75,000 kilograms of dried...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 9,960 40-ml units of its SYNC 25 CBD oil to Alberta and Saskatchewan. The Emerald-branded Indica-dominant CBD oil offers consumers a smoke-free product alternative....

Emerald Health Therapeutics, Inc. (“Emerald” or “the Company”) (TSXV: EMH; OTCQX: EMHTF) commends the Government of Ontario for its newly announced plans to expand the province’s brick-and-mortar retail sales network for adult-use cannabis. Emerald...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), through its joint venture Emerald Health Naturals (“EHN”), has introduced a cannabis-free herbal and botanical endocannabinoid-supporting health supplement product line in...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received its initial cultivation license from Health Canada for its new organic cannabis growing facility in Metro Vancouver, BC. Tailor-made for Emerald to produce...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) is pleased that today the Government of Canada released the final regulatory framework for ingestibles and edibles. “The clarity of the final regulatory framework provides...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, will participate in the Oppenheimer 19th Annual Consumer Growth and E-Commerce Conference on...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reports that is has expanded its agreement to purchase harvested hemp flower and leaf, or hemp chaff, from Emerald Health Hemp Inc. (“EHH”) from 1,000 to 1,200 acres for 2019....

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in multiple upcoming investment and industry conferences in June. Lift & Co. Cannabis Expo Allan Rewak, Vice President, Communications & Stakeholder...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended March 31, 2019. Full versions of the Company’s unaudited condensed, interim consolidated financial statements and MD&A...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received its first purchase order from Société Québécoise du Cannabis (SQDC) to supply its cannabis products to the Quebec recreational cannabis market. Emerald is...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have received 2,129,707 shares of...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US...

Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has appointed Sean Rathbone as Chief Operating Officer. Mr. Rathbone brings expertise in operational leadership, corporate process management, technology advancement, and waste...

Emerald Health Therapeutics, Inc.(“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will host its first quarter 2019 financial results conference call on Friday, May 31st, 2019 at 10:30 a.m. ET. The Company will report its financial results for the first...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received a Standard Processing License (the...

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

NEW YORK, May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, in partnership with Midtown Partners & Co, LLC, today announced that the presentations from the Cannastocks2019 Q1 Virtual lnvestor Conference are available for on-demand viewing. The event featured presentations by public companies, providing insight on innovation, consolidation, international expansion and specialization in the fast-growing cannabis industry.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the British Columbia Liquor Distribution Branch (BCLDB). The Emerald-branded pure CBD oil offers consumers a non-THC,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in Cowen’s Toronto Cannabis Summit on May 22 in Toronto. Dr. Avtar Dhillon, President and Executive Chairman of Emerald, will be a panelist on the Canadian...

Public Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.com

NEW YORK, May 14, 2019 /PRNewswire/ -- Virtual Investor Conferences, in partnership with Midtown Partners & Co, LLC, today announced the agenda for the upcoming Cannastocks2019 Q1 Virtual lnvestor Conference. Individual investors, institutional investors, advisors, and analysts are invited to listen and watch live. The event will feature presentations by public companies, providing insight on innovation, consolidation, international expansion and specialization in the fast-growing cannabis industry. The program opens at 9:00 AM ET on Wednesday, May 15th.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has been authorized by PEI Cannabis and Manitoba Liquor & Lotteries Corporation to supply Emerald-branded cannabis products into those provinces. Emerald has also fulfilled its...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the fourth quarter and year ended December 31, 2018. Highlights Emerald’s Q4 sales of $1.1 million was more than triple the prior quarter...

Emerald Health Therapeutics, Inc. (TSXV:EMH) (“Emerald” or the “Company”) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have elected to receive $7.5...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its 50%-owned joint venture, Pure Sunfarms, has completed planting of the final quadrants of its 1.1 million square foot Delta 3 greenhouse operation in...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, announced today that executives of the company will participate in multiple upcoming investment...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its Québec facility, Verdélite, has received its Standard Processing License from Health Canada. This license means that, in addition to Verdélite’s right...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has signed a letter of intent to supply cannabis to the Société Québécoise du Cannabis (SQDC), Quebec's sole legal distributor of recreational cannabis. Under the agreement,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its 50%-owned joint venture, Pure Sunfarms, has exercised its option to acquire from Village Farms International, Inc. (“Village Farms”) a second 1.1...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first purchase order of cannabis from Yukon Liquor Corporation, signed a sales agreement with Alberta Gaming, Liquor and Cannabis (AGLC), and become...

Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV:EMH; OTCQX:EMHTF) today announced that it has established an at-the-market equity program (“ATM Program”) that allows the Company to issue common shares from treasury (“Common...

Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV: EMH; OTCQX: EMHTF) applauds the Government of Canada for proposing to amend the excise tax calculation for cannabis in the federal budget announced yesterday. The implementation...

Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced today that Allan Rewak has been appointed Vice President, Communications and Stakeholder Relations, effective April 15, 2019. Prior to joining...

Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) has fulfilled its first purchase order of cannabis from Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”). “As we scale up...

Cannabis sales have been soaring since legalization in Canada but there's a lot more to come as the industry continues to change. With more retailers opening for business and the edibles market likely coming online this year, there's going to be...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), received from Health Canada...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner’s, (Emerald Health Bioceuticals or “EHB”), Endo Bliss, won Taste For Life’s 2019 Essentials Supplement Award, which recognizes the...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced the launch of Verdélite Sciences Inc. ("Verdélite"), a wholly-owned, Québec-based production subsidiary licensed by Health Canada. Formerly known as...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit...

Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across...

Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its...

Emerald Health Therapeutics, Inc. (TSXV:EMH) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San...

Emerald Health Therapeutics, Inc. ("Emerald" or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth...

Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) ("Emerald" or the “Company”) closed today its prospectus sale (the “Offering”) to a single Canadian institutional accredited investor (the “Investor”) announced on December 3, 2018. Pursuant...

Emerald Health Therapeutics Inc. ("Emerald" or “the Company”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to...

Emerald Health Therapeutics, Inc. (TSXV:EMH) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to...

Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the three and nine months ended September 30, 2018. They are available for viewing...

Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. “Emerald’s...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been appointed President of Agro-Biotech, its Québec-based licensed cannabis production operation, effective November 26,...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based...

MediPharm Labs Corp. (“MediPharm Labs” or the “Company”) (TSXV: LABS) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and...

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these...

Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. Mr. Dillman previously served as Vice President of Sales and...

MediPharm Labs Corp. ("MediPharm") (TSXV: LABS) is pleased to announce that it has entered into a Cannabis Concentrate Program Agreement (the "Agreement") with Emerald Health Therapeutics Inc. ("Emerald") (TSXV: EMH - OTCQX:EMHTF). Pursuant to the...